[ad_1]
Criticism of the federal government for the slowness of vaccination against the coronavirus across the country is growing stronger. A member of Leopoldina even sees a “serious failure” among those responsible.
Given the slow start of corona vaccination, a member of the Leopoldina National Academy of Sciences accused the federal government of serious failures in the acquisition of vaccines.
“I consider the current situation to be a great failure of those responsible,” said neurologist Frauke Zipp of the daily “Die Welt”. “Why didn’t he order a lot more vaccines at risk in the summer?” Emphasized Zipp, who is the director of the neurology clinic and polyclinic at Johannes Gutenberg University in Mainz and advises the Rhineland-Palatinate state government.
“Recently there was still an official commemoration of the dead, now apparently they no longer count all the days in which human lives could be saved. Now patience is required,” Zipp criticized, referring to vaccines.
Vaccination coverage of 60 percent of the population in two or three months?
In Germany, if enough vaccine is available, 60 percent of the population can be vaccinated within two to three months, Zipp said. “Criticism of the vaccine procurement must be taken very seriously,” FDP Secretary General Volker Wissing told “Welt”.
“We can see from the example of Israel and other countries that it is possible to vaccinate more quickly. The federal government must explain very well why things are going so slowly in Germany.”
“The vaccination strategy is a race against time”
The leftist leader, Bernd Riexinger, was “a bit surprised by the few doses of vaccine that the EU has ordered.” The federal government should now “quickly issue licenses for the post-production of the Biontech / Pfizer vaccine.” That is directly in the hand of the Minister of Health, Jens Spahn (CDU). The mutation of the virus in Britain makes it clear: “A successful vaccination strategy is also a race against time.”
Kordula Schulz-Asche of the Green parliamentary group told “Welt” that “from today’s perspective, it would have been better to order more and different vaccines from the more than 100 developers at risk.” However, he noted that the Biontech vaccine was still in the testing phase in the summer.
